Yarrow Bioscience (NASDAQ:YARW) Upgraded at Wall Street Zen

Wall Street Zen upgraded shares of Yarrow Bioscience (NASDAQ:YARW) to a hold rating in a report released on Saturday.

Several other equities analysts have also commented on the company. TD Cowen assumed coverage on Yarrow Bioscience in a research report on Tuesday, July 28th. They set a “buy” rating on the stock. BTIG Research assumed coverage on shares of Yarrow Bioscience in a research report on Monday, August 3rd. They issued a “buy” rating and a $58.00 price objective for the company. Two analysts have rated the stock with a Buy rating, Based on data from MarketBeat.com, the company currently has a consensus rating of “Buy” and a consensus price target of $58.00.

Yarrow Bioscience Stock Up 8.5%

Shares of NASDAQ YARW opened at $39.50 on Friday. Yarrow Bioscience has a 1-year low of $14.02 and a 1-year high of $46.95. The stock has a market capitalization of $105.47 million, a PE ratio of -2.70 and a beta of 1.95.

Yarrow Bioscience Company Profile

VYNE Therapeutics Inc, a pharmaceutical company, focuses on developing various therapeutics for the treatment of immuno-inflammatory conditions. The company develops FCD105, a topical combination foam that has completed Phase III clinical trials for the treatment of moderate-to-severe acne vulgaris; and FMX114, a combination of tofacitinib, which is in Phase IIa preclinical trial for the treatment of mild-to-moderate atopic dermatitis. It is also developing VYN201, a bromodomain and extra-terminal (BET) inhibitor for various immuno-inflammatory diseases, including skin diseases; and VYN202, BET inhibitor compounds that are selective for bromodomain 2.